Vitamin D3 ameliorates herpes simplex virus-induced Behçet's disease-like inflammation in a mouse model through down-regulation of Toll-like receptors

Clinical and Experimental Rheumatology

Volumn 29, Issue 4 SUPPL. 67, 2011, Pages

  Choi, B ^a   Lee, E S ^b   Sohn, S ^a,c  

^a Ajou University   (South Korea)

^b Ajou University School of Medicine   (South Korea)

^c Yonsei University   (South Korea)

Author keywords

Beh et's disease; Herpes simplex virus; Mouse model; TLR; TNF alpha; Vitamin D3

Indexed keywords

25 HYDROXYVITAMIN D; COLECALCIFEROL; CYTOKINE; INTERLEUKIN 6; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; CALCIFEDIOL; COLCHICINE; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHCET DISEASE; CONTROLLED STUDY; DOWN REGULATION; HERPES SIMPLEX VIRUS; INFLAMMATION; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; ANIMAL CELL; ANIMAL CELL CULTURE; ASYMPTOMATIC DISEASE; CALCIFEDIOL BLOOD LEVEL; CELL ISOLATION; DRUG EFFECT; DRUG MECHANISM; IMMUNOREGULATION; IN VITRO STUDY; MALE; RECEPTOR DOWN REGULATION; SYMPTOM; VITAMIN BLOOD LEVEL;

ANIMALS; BEHCET SYNDROME; CELLS, CULTURED; CHOLECALCIFEROL; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; HERPES SIMPLEX; HERPESVIRUS 1, HUMAN; INTERLEUKIN-6; MACROPHAGES, PERITONEAL; MALE; MICE; MICE, INBRED ICR; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR-ALPHA; VITAMIN D; VITAMINS;

EID: 80855144099     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. SUZUKI Y, ICH1YAMA T, OHSAKI A, HASEGAWA S, SHIRA1SM M, FURUKAWA S: Antiinflammatory effect of lalpha,25-dihydroxyvitamin D(39 in human coronary arterial endothelial cells: Implication for the treatment of Kawasaky disease. J. Steroid. Biochem. Mol Biol 2009; 113: 134-8.
2. GERRITSEN MJ, BOEZEMAN JB, VAN VLIJMEN- WILLEMS IM, VAN DE KERKHOF PC: The effect of tacalcitol (1,24(OH)2D3) on cutaneous inflammation, epidermal proliferation and keratinization in psoriasis: a placebo-controlled, double-blind study. Br J Dermatol 1994; 131:57-63. (Pubitemid 24234289)
3. ZEHNDER D, QUINKLER M, EARDLEY KS et al.\ Reduction of the vitamin D hormonal system in kidney disease is associated with increased renal inflammation. Kidney Int 2008; 74: 1343-53.
4. DO JE, KWON SY, PARK S, LEE ES: Effects of vitamin D on expression of Toll-like receptors of monocytes from patients with Behçet's disease. Rheumatology (Oxford) 2008; 47: 840-8. (Pubitemid 351796370)
5. PEDERSEN LB, NASHOLD FE, SPACH KM, HAYES CE: 1,25-dihydroxyvitamin D3 reverses experimental autoimmune encephalomyelitis by inhibiting chemokine synthesis and monocyte trafficking. J Neurosci Res 2007; 85: 2480-90. (Pubitemid 47204762)
6. SADEGHI K, WESSNER B, LAGGNER U et al.: Vitamin D3 down-reGÜLates monocyte TLR expression and triggers hyporesponsiveness to pathogen-associated molecular patterns. Eur J Immunol 2006; 36: 361-70. (Pubitemid 43257459)
7. PRABHU ANAND S, SELVARAJ P, NARAYANAN PR: Effect of 1,25 dihydroxyvitamin D3 on intracellular IFN-gamma and TNFalpha positive T cell subsets in pulmonary tuberculosis. Cytokine 2009; 45: 105-10.
8. ZOUBOULIS CC, KATSANTONIS J, KETTELER R et al.: Adamantiades- Behçet's disease: interleukin- 8 is increased in serum of patients with active oral and neurological manifestations and is secreted by small vessel endothelial cells. Arch Dermatol Res 2000; 292: 279-84. (Pubitemid 30386437)
9. CHOI B, HWANG Y, KWON HJ et al.: Tumor necrosis factor alpha small interfering RNA decreases herpes simplex virus-induced inflammation in a mouse model. J Dermatol Sci 2008; 52: 87-97.
10. SECKIN D, AKPOLAT T, OLTULU Y et al.: Serum lipoprotein (a) levels in Behçet's disease. Br J Dermatol 1995; 133: 342.
11. MUFTUOGLU AU, YAZICI H, YURDAKUL S et al.: Relation of serum Creactive protein and erythrocyte sedimentation rates to disease activity. Int J Dermatol 1986; 25: 235-9. (Pubitemid 16115709)
12. AL-DALAAN A, AL-SEDAIRY S, AL-BALAA S, AL-JANADI M, ELRAMAHI K, BAHABRI S: Enhanced interleukin 8 secretion in circulation in patients with Behçet's disease. J Rheumatol 1995; 22: 904-7.
13. KATSANTONIS J, ADLER Y, ORFANOS CE, ZOUBOULIS CC: Adamantiades- Behçet's disease: serum IL-8 is more reliable marker for disease activity than C-reactive protein and erythrocyte sedimentation rate. Dermatology 2000; 201: 37-9.
14. SAYINALP N, OZCEBE OI, OZDEMIR O, HAZNEDAROǦLUIC, DUNDAR S, KIRAZLI S: Cytokines in Behçet's disease. J Rheumatol 1996;23:321-2.
15. SOHN S, LEE ES, BANG D, LEE S: Behçet's disease-like symptoms induced by the Herpes simplex virus in ICR mice. Eur J Dermatol 1998;8:21-3. (Pubitemid 28264144)
16. ADAM B, CALIKOGLU E: Serum interleukin- 6, procalcitonin and C-reactive protein levels in subjects with active Behçet's disease. J Eur Acad Dermatol Venereol 2004; 18: 318-20. (Pubitemid 38618329)
17. XU XH, SHAH PK, FAURE E et al.: Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upreGÜLated by oxidized LDL. Circulation 2001; 104: 3103-8. (Pubitemid 34014065)
18. NARA K, KUROKAWA MS, CHIBA S et al: Involvement of innate immunity in the pathogenesis of intestinal Behçet's disease. Clin Exp Immunol2008; 152: 245-51. (Pubitemid 351520909)
19. BANG D: Treatment of Behçet's disease. YonseiMedJ 1997;38:401-10.
20. KAKLAMANI VG, KAKLAMANIS PG: Treatment of Behçet's disease-an update. Semin Arthritis Rheum 2001; 30: 299-312.
21. AKDENIZ N, ESREFOGLU M, KELES MS, KARAKUZU A, ATASOY M: Serum interleukin- 2, interleukin-6, tumour necrosis factor- alpha and nitric oxide levels in patients with Behçet's disease. Ann Acad Med Singapore 2004; 33: 596-9. (Pubitemid 39626965)
22. KALLEN KJ: The role of trans signalling via the agonistic soluble IL-6 receptor in human diseases. Biochim Biophys Acta 2000; 1592: 323-43.
23. HEINRICH PC, CASTELL JV, ANDUS T: Interleukin-6 and the acute phase response. Biochem 1990;265:621-36. (Pubitemid 20053863)
24. HIRANO T: Interleukin-6 and its relation to inflammation and disease. Clin Immunol Immunopathol 1992; 62: 60-5.
25. YAMAKAWA Y., SUGITA Y., NAGATANI T. et al.: Interleukin-6 (IL-6) in patients with Behçet's disease. J Dermatol Sci 1996; 11: 189-95.
26. LINKSWANG CR, CHUANG CY, CHEN CY: Anticardiolipin antibodies and interleukin-6 in cerebrospinal fluid and blood of Chinese patients with neuro-Behçet's syndrome. Clin Exp Rheumatol 1992; 10: 599-602.
27. BARDAK Y, ARIDOGAN BC: The demonstration of serum interleukin 6-8, tumor necrosis factor-alpha, complement, and immunoglobulin levels in Behçet's disease with ocular involvement. Ocul Immunol lnflamm 2004; 12:53-8. (Pubitemid 38406453)
28. EDWARDS CK: Drug Discovery and Development for Inflammatroy Diseases. Expert Opin Ther Targets 2004; 8: 151-63.
29. PIEMONTI L, MONTI P, SIRONI M et al.: Vitamin D3 affects differentiation, maturation, and function of human monocyte-derived dendritic cells. J Immunol 2000; 164: 4443-51. (Pubitemid 30238038)
30. MORO JR, IWATA M, VON ANDRIANO UH: Vitamin effects on the immune system: vitamins A and D take centre stage. Nat Rev Immunol 2008; 8: 685-98.
31. KIRINO Y, TAKENO M, WATANABE R et al.: Association of reduced heme oxygenase-1 with excessive Toll-like receptor 4 expression in peripheral blood mononuclear cells in Behçet's disease. Arthritis Res Ther 2008; 10:R16.
32. TAKEDA K, AKIRA S: TLR signaling pathways. Semin Immunol 2004; 16:3-9. (Pubitemid 38147427)
33. ABDOLLAHI-ROODSAZ S, JOOSTEN LA, KOENDERS MI et al.: Stimulation of TLR2 and TLR4 differentially skews the balance of T cells in a mouse model of arthritis. J Clin Invest 2008; 118:205-16.
34. PEDRERA JD, CANAL ML, CARVAJAL J et al.: Influence of vitamin D administration on bone ultrasound measurements in patients on anticonvulsant therapy. Eur J Clin Invest 2000; 30: 5-899.
35. RUCKER D, TONELLI M, COLES MG, YOO S, YOUNG K, MCMAHON AW: Vitamin D insufficiency and treatment with oral vitamin D3 in northern-dwelling patients with chronic kidney disease J Nephrol 2009; 22: 75-82.
36. HASKARD D: Behçet's disease. Medicine 2006; 34: 493-5.
37. SUN A, WANG YP, CHIA JS, LIU BY, CHIANG CP: Treatment with levamisole and colchicine can result in a significant reduction of IL-6, IL-8 orTNF-alpha level in patients with mucocutaneous type of Behçet's disease. J Oral Pathol Med 2009; 38: 401-5.
38. SHIM J, BYUN HO, LEE YD, LEE ES, SOHN S: Interleukin-6 small interfering RNA improved the herpes simplex virus-induced systemic inflammation in vivo Behçet's disease- like mouse model. Gene Ther 2009; 16: 415-25.
39. EVEREKLIOGLU C, ER H, TURKOZ Y, CEKMEN M: Serum levels of TNF-alpha, sIL-2R, IL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Behçet's disease. Mediators lnflamm 2002; 11:87-93. (Pubitemid 34526411)
40. RIBI C, SZTAJZEL R, DELAVELLE J, CHIZZOLINI C: Efficacy of TNF alpha blockade in cyclophosphamide resistant neuro-Behçet disease. J Neurol Neurosurg Psychiatry 2005; 76: 1733-5. (Pubitemid 41697647)
41. GIANSANTI F, BARBERA ML, VIRGILI G, PIERI B, EMMI L, MENCHINI U: Infliximab for the treatment of posterior uveitis with retinal neovascularization in Behçet disease. Eur J Ophthalmol 2004; 14: 445-8. (Pubitemid 39481952)
42. OLIVIERI I, D' ANGELO S, PADULA A, LECCESE P, MENNILLO GA: Successful treatment of recalcitrant genital ulcers of Behçet's disease with adalimumab after failure of infliximab and etanercept. Clin Exp Rheumatol 2009; 27 (Suppl. 53): S112.
43. BELZUNEGUI J, LÓPEZ L, PANIAGUA I, 1NTXAUSTIJJ, MAfZ O: Efficacy of infliximab and adalimumab in the treatment of a patient with severe neuro-Behçet's disease. Clin Exp Rheumatol 2008; 26 (Suppl. 50): S133-4.